RxLogix Hosts Record Turnout at the 24th Annual Euromeeting DIA Conference

Introducing two new software solutions.

Aliso Viejo, CA (PRWEB) April 19, 2012

RxLogix Corporation (http://www.rxlogix.com), the most experienced team of global Safety and Risk Management experts offering consulting and strategic software solutions, today announced results from their recent participation at the 24th annual Euromeeting of the Drug Information Association (DIA) in Copenhagen, Denmark. This was RxLogix's first time participating at Euro DIA, however, the customer awareness and executive level participation demonstrated RxLogix's global visibility and reach as a key player in Safety and Risk Management initiatives for all biopharmaceutical, medical device and CRO organizations. Over 300 attendees, including a substantial number of senior executives from several EMEA headquartered organizations, visited the RxLogix exhibit and previewed the new RxLogix solutions and services announced during Euro DIA.

RxLogix's CEO Raj More commented “I am very pleased with RxLogix's reception by the attendees at the Euro DIA and impressed with the amount of interest in our products and services." Initial contact with key industry professionals resulted in a real interest in RxLogix and its products. The new products unveiled at Euro DIA included PV Central, an executive dashboard for compliance, productivity and risk management business metrics, and ClinSafety, the industry's first bidirectional EDC to Safety integrated solution from any EDC to any drug safety system. RxLogix's John Loucks, Head of Global Sales and Marketing, commented “it is clear the Life Sciences industry is looking for expert knowledge and solutions that provide real value and cost savings. Every client who saw the RxLogix products commented these products solve an important need and several have requested or begun evaluations at their locations.” The RxLogix team at Euro DIA included Amanda Bowles, Global Practice Director and Dr. Peter Nowicki, Global Practice Director and a contributor and co-author for the new European Pharmacovigilance Regulations scheduled to begin this summer.

RxLogix looks forward to the up-coming US DIA trade-show this June in Philadelphia and expects this event will be even more successful with the formal launch in the US of PV Central and ClinSafety. To arrange a meeting with the RxLogix executives, please contact Chief Sales and Marketing Officer John Loucks at 570-472-3459 or email john(dot)loucks(at)rxlogix(dot)com.

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/4/prweb9414367.htm